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Review methods
MEDLINE, EMBASE/Excerpta Medica (both to Aug 2012), and reference lists of included studies and reviews were searched for randomized controlled trials (RCTs). 11 RCTs (n = 5207, median follow-up 12 mo) met selection criteria; 8 trials involved HF patients (n = 4563), and 3 trials involved AMI patients (n = 644). 4 RCTs had Jadad quality scores ≥ 3 out of 5, 4 trials had adequate allocation concealment, and 6 had blinding.
Main results
Meta-analysis showed that in patients with HF, carvedilol reduced all-cause mortality but not HF-related readmissions compared with the β 1 -selective β-blockers (Table) . In patients with AMI, results for all-cause mortality varied when a random-effects or fixed-effect model was used; nonfatal MI did not differ between treatment groups (Table) .
Conclusions
Carvedilol reduces all-cause mortality compared with the β 1 -selective β-blockers in patients with heart failure. In patients with acute myocardial infarction, results are not conclusive. tartrate, which have not been shown to have benefit in HF patients, rather than the doses of metoprolol succinate that have shown efficacy, resulting in a bias toward carvedilol. The validity of this meta-analysis is further reduced since the 7 remaining RCTs were small and included different patient populations, and sensitivity analysis to assess the superiority of carvedilol without COMET was not done. Other outcomes in the meta-analysis included HF readmissions in patients with HF and all-cause mortality and nonfatal MI in patients with AMI. Once again, these secondary analyses were not instructive due to the overwhelming weight of COMET and small size of the remaining trials.
Are the benefits of β-blockers a class effect, or do some β-blockers reign supreme? The network meta-analysis by Chatterjee and colleagues provides the best evidence to date that there is at least a class effect, but the superiority issue is still debatable. The network meta-analysis suggests that carvedilol may provide more mortality benefit and better tolerability than other β-blockers (although not statistically significant), which is supported by several small trials in the traditional meta-analysis by DiNicolantonio and colleagues. Further large RCTs are needed to compare the relative efficacy of β-blockers in this population. Until then, clinicians would be best served to use carvedilol, metoprolol succinate, or bisoprolol, the
